Literature DB >> 1666494

Daptomycin disrupts membrane potential in growing Staphylococcus aureus.

W E Alborn1, N E Allen, D A Preston.   

Abstract

Daptomycin (LY146032) caused a calcium-dependent dissipation of the membrane potential (delta psi) in Staphylococcus aureus without noticeably affecting the chemical gradient (delta pH) across the membrane. The effect of daptomycin on membrane energization may account for many of the inhibitory effects on macromolecular biosyntheses and membrane function reported for this antibiotic. Our evidence indicates that the bactericidal activity of daptomycin is dependent on an available delta psi.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1666494      PMCID： PMC245372          DOI： 10.1128/AAC.35.11.2282

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  Inhibition of peptidoglycan biosynthesis in gram-positive bacteria by LY146032.

Authors:  N E Allen; J N Hobbs; W E Alborn
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

2.  The effect of cultural conditions on the activity of LY146032 against staphylococci and streptococci.

Authors:  J H Andrew; M C Wale; L J Wale; D Greenwood
Journal:  J Antimicrob Chemother       Date:  1987-08       Impact factor: 5.790

3.  The use of flow dialysis for determinations of deltapH and active transport.

Authors:  S Ramos; S Schuldiner; H R Kaback
Journal:  Methods Enzymol       Date:  1979       Impact factor: 1.600

4.  In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic.

Authors:  G M Eliopoulos; S Willey; E Reiszner; P G Spitzer; G Caputo; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

5.  The lipopeptide antibiotic A21978C has a specific interaction with DMPC only in the presence of calcium ions.

Authors:  J H Lakey; R Maget-Dana; M Ptak
Journal:  Biochim Biophys Acta       Date:  1989-10-02

Review 6.  Bacterial uptake of aminoglycoside antibiotics.

Authors:  H W Taber; J P Mueller; P F Miller; A S Arrow
Journal:  Microbiol Rev       Date:  1987-12

7.  In vitro activity and mechanism of action of A21978C1, a novel cyclic lipopeptide antibiotic.

Authors:  G M Eliopoulos; C Thauvin; B Gerson; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

8.  Fluorescence indicates a calcium-dependent interaction between the lipopeptide antibiotic LY146032 and phospholipid membranes.

Authors:  J H Lakey; M Ptak
Journal:  Biochemistry       Date:  1988-06-28       Impact factor: 3.162

9.  Lipoteichoic acid as a new target for activity of antibiotics: mode of action of daptomycin (LY146032).

Authors:  P Canepari; M Boaretti; M M Lleó; G Satta
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

10.  The role of acyl chain character and other determinants on the bilayer activity of A21978C an acidic lipopeptide antibiotic.

Authors:  J H Lakey; E J Lea
Journal:  Biochim Biophys Acta       Date:  1986-07-24
View more
  66 in total

1.  Resistance studies with daptomycin.

Authors:  J A Silverman; N Oliver; T Andrew; T Li
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  In vitro activity of daptomycin against gram-positive European clinical isolates with defined resistance determinants.

Authors:  Ad C Fluit; Franz-Josef Schmitz; Jan Verhoef; Dana Milatovic
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

3.  Assessment of two commercial susceptibility test methods for determination of daptomycin MICs.

Authors:  James H Jorgensen; Sharon A Crawford
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

4.  Diminished macrophage inflammatory response to Staphylococcus aureus isolates exposed to daptomycin versus vancomycin or oxacillin.

Authors:  B Keith English; Erik M Maryniw; Ajay J Talati; Elizabeth A Meals
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

5.  Clinical rationale for treatment of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycin.

Authors:  Zukile Gqada; Ben Marais; Elizabeth Wasserman; Colleen Bamford; Heidi Orth; George Sakoulas; Warren Rose; Michael J Rybak; Satish Pillai; Jeff Alder; Robert C Moellering; George M Eliopoulos
Journal:  J Clin Microbiol       Date:  2008-07       Impact factor: 5.948

6.  Incorporation of exogenous fatty acids protects Enterococcus faecalis from membrane-damaging agents.

Authors:  Holly E Saito; John R Harp; Elizabeth M Fozo
Journal:  Appl Environ Microbiol       Date:  2014-08-15       Impact factor: 4.792

Review 7.  A current perspective on daptomycin for the clinical microbiologist.

Authors:  Romney M Humphries; Simon Pollett; George Sakoulas
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

8.  Comparative mechanistic studies of brilacidin, daptomycin, and the antimicrobial peptide LL16.

Authors:  Bruk Mensa; Gabriella L Howell; Richard Scott; William F DeGrado
Journal:  Antimicrob Agents Chemother       Date:  2014-06-16       Impact factor: 5.191

9.  Use of multivariate analysis to compare antimicrobial agents on the basis of in vitro activity data.

Authors:  J M Hernández; P Conforti
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

10.  In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin.

Authors:  K C Lamp; M J Rybak; E M Bailey; G W Kaatz
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.